
Investors Face August Deadline in ADMA Biologics Securities Lawsuit
Investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, have until August 10 to seek appointment as lead plaintiff in a class action lawsuit. Filed in the District of New Jersey, the case alleges the company misled shareholders regarding its revenue growth and internal controls.










.png)














